Brokerages expect Insmed Incorporated (NASDAQ:INSM – Get Rating) to announce sales of $53.63 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Insmed’s earnings. The highest sales estimate is $56.20 million and the lowest is $51.43 million. Insmed reported sales of $40.21 million in the same quarter last year, which indicates a positive year over year growth rate of 33.4%. The firm is expected to issue its next earnings report before the market opens on Monday, January 1st.
On average, analysts expect that Insmed will report full-year sales of $255.87 million for the current financial year, with estimates ranging from $245.78 million to $273.14 million. For the next year, analysts forecast that the company will report sales of $343.75 million, with estimates ranging from $318.97 million to $375.29 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Insmed.
Insmed (NASDAQ:INSM – Get Rating) last posted its quarterly earnings data on Thursday, February 17th. The biopharmaceutical company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.06). The firm had revenue of $56.10 million for the quarter, compared to analysts’ expectations of $50.84 million. Insmed had a negative return on equity of 102.11% and a negative net margin of 230.63%. The firm’s quarterly revenue was up 35.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.00) earnings per share.
NASDAQ INSM opened at $23.56 on Tuesday. The company has a quick ratio of 5.70, a current ratio of 6.19 and a debt-to-equity ratio of 1.41. The company has a fifty day moving average of $23.58 and a two-hundred day moving average of $25.73. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of -6.09 and a beta of 2.15. Insmed has a 52 week low of $20.02 and a 52 week high of $36.97.
In related news, CEO William Lewis sold 96,614 shares of Insmed stock in a transaction dated Wednesday, March 23rd. The stock was sold at an average price of $23.16, for a total value of $2,237,580.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.63% of the company’s stock.
A number of institutional investors have recently made changes to their positions in INSM. Millennium Management LLC raised its holdings in Insmed by 62.8% in the second quarter. Millennium Management LLC now owns 11,753 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 4,534 shares in the last quarter. Amalgamated Bank raised its holdings in Insmed by 4.8% in the third quarter. Amalgamated Bank now owns 20,435 shares of the biopharmaceutical company’s stock worth $563,000 after purchasing an additional 936 shares in the last quarter. SG Americas Securities LLC raised its holdings in Insmed by 130.6% in the third quarter. SG Americas Securities LLC now owns 77,011 shares of the biopharmaceutical company’s stock worth $2,121,000 after purchasing an additional 43,618 shares in the last quarter. Swiss National Bank raised its holdings in Insmed by 10.4% in the third quarter. Swiss National Bank now owns 250,800 shares of the biopharmaceutical company’s stock worth $6,907,000 after purchasing an additional 23,700 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in Insmed by 4.9% in the third quarter. Principal Financial Group Inc. now owns 757,514 shares of the biopharmaceutical company’s stock worth $20,861,000 after purchasing an additional 35,722 shares in the last quarter.
About Insmed (Get Rating)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
- Get a free copy of the StockNews.com research report on Insmed (INSM)
- Is Cleveland-Cliffs Stock a Safe Bet After Earnings?
- MarketBeat Podcast: Profit From Diversifying Trading Strategies
- Hasbro Insider Bets Big On Stock Rebound
- The Coca-Cola Company Gets KO’d After Stunning Quarter
- Schwab Stock Can Be Caught Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.